Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11187 Views
-
Last post by NHE
-
- 0 Replies
- 1039 Views
-
Last post by NHE
-
- 0 Replies
- 1838 Views
-
Last post by frodo
-
- 0 Replies
- 1204 Views
-
Last post by frodo
-
- 0 Replies
- 1970 Views
-
Last post by NHE
-
- 0 Replies
- 1669 Views
-
Last post by frodo
-
- 0 Replies
- 1179 Views
-
Last post by NHE
-
- 1 Replies
- 1673 Views
-
Last post by frodo
-
- 0 Replies
- 2225 Views
-
Last post by NHE